Speciality Medicines IPO- Company Analysis
Speciality Medicines IPO has been launched on the SME IPO platform at a bookbuilding issue of Rs. 29.14 Cr. Speciality Medicines Limited is engaged in the marketing and distribution of finished specialty pharmaceuticals both in the domestic as well as in the overseas markets including high-value oral and injectable medications designed for the treatment of complex and chronic diseases.
The company’s portfolio comprises a wide range of specialty pharmaceuticals finished formulated products such as Tablets, Capsule, Cream, Syrup, Eye Drop, Gel, Infusion, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic Solution, Oral Solution, Sachet, Suspension
The Company has two models of operation:
(a) Marketing and distribution of specialty pharmaceuticals goods and
(b) Contract formulation of finished pharmaceuticals for export
Speciality Medicines IPO Details
The Speciality Medicines IPO is going to open on 20 March 2026. The initial public offering will close on 24 March. The IPO allotment will happen on 25 March and the refund will be initiated on 27 March 2026.
The IPO is for Rs. 29.14 crore and the new SME IPO's fresh issue is of 0.24 crore shares.
The expected IPO listing date for Speciality Medicines is probably Monday, March 30, 2026, when they will list on BSE and SME.
The Speciality Medicines IPO price band is set at ₹117 to ₹124.
IPO Timetable (Tentative)
| Events | Date |
| IPO Opening Date | Mar 20, 2026 |
| IPO Closing Date | Mar 24, 2026 |
| IPO Allotment Date | Mar 25, 2026 |
| Refund Initiation | Mar 27, 2026 |
| IPO Listing Date | Mar 30, 2026 |
Click to open free demat account and apply for the IPO.
Company Financials
(Amount in Cr)
| Particulars | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 45.57 | 39.98 | 22.68 |
| Total Income | 36.93 | 58.54 | 27.66 |
| Profit After Tax | 6.06 | 8.61 | 2.93 |
| EBITDA | 6.51 | 9.09 | 5.26 |
| Net Worth | 36.47 | 30.42 | 15.06 |
| Reserves and Surplus | 30.04 | 23.98 | 9.95 |
| Total Borrowing | 4.81 | 5.05 | 2.86 |
Cash Flows
(Amount in lac)
| Net Cash Flow | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Net Cash Flow Operating Activities | (579.44) | (480.02) | (365.31) |
| Net Cash Flow Investing Activities | (206.90) | (2.52) | (11.80) |
| Net Cash Flow Financing Activities | 846.01 | 481.28 | 387.50 |
Revenue Bifurcation
(Rs. in Lac)
(Source: RHP)
The Objective of the Issue
The company aims to utilize Net Proceeds from the Issue for the following objectives:
- Marketing and Advertising Cost. ~ Rs. 1.66 Cr.
- Establishing a Research and Development (R&D) Centre at Revenue City, Dist. Valsad, Gujarat. ~ Rs. 12.68 Cr.
- International Market Product Registration and Development for International Market. ~ Rs. 2.99 Cr.
- Working Capital Requirements. ~Rs. 8.00 Cr.
- General Corporate Purposes.
Listed Peers of Speciality Medicines Ltd.
| Name of Company | Face Value (₹) | Basic EPS (₹) | PE Ratio (x) |
| Remus Pharmaceuticals Limited | 10 | 65.21 | 10.41 |
| Trident Lifeline Limited | 10 | 10.22 | 27.00 |
| Mono Pharmacare Limited | 10 | 1.75 | 7.49 |
Valuation
| KPI | Value |
| ROE | 37.85% |
| ROCE | 33.39% |
| Debt/Equity | 0.17 |
| RoNW | 28.30% |
| PAT Margin | 14.77% |
| EBITDA Margin | 15.60% |
| Price to Book Value | 2.62 |
Evaluation of P/E Ratio
Based on EPS of Rs. 14.10 for the period ending FY 2025, the P/E ratio works out to 8.79x.
Explore the Tipco Engineering India IPO.
IPO's Strengths
- Diverse Global Presence
- Variety of Products
- Long-term Relationships with Customers
- Competent Promoters and Management Team.
IPO's Weaknesses
- Risk due to Supplier Dependency
- Risk of Quality Compliance
- Risk regarding Research and Development.
Speciality Medicines IPO GMP (Grey Market Premium)
As of 18 Mar 2026, Speciality Medicines IPO GMP has not started yet.
Speciality Medicines IPO Summary
| IPO Opening & Closing Date | 20 Mar, 2026 to 24 Mar, 2026 |
| Face Value | Rs. 10 per Share |
| Issue Price | Rs. 117 to Rs. 124 per Share. |
| Lot Size | 1000 Shares |
| Issue Size | 23,50,000 Shares (Rs. 29 Cr) |
| Offer for Sale | - |
| Fresh Issue | 23,50,000 Shares (Rs. 29 Cr) |
| Listing at | BSE, SME |
| Issue Type | Bookbuild issue IPO |
| Registrar | Skyline Financial Services Pvt. Ltd. |
IPO Lot Details
While HNI investors can invest at least 3 Lots (3000 Shares) at Rs. 3,72,000, Retail investors can invest in 2 Lots (i.e. 2000 Shares) at Rs. 2,48,000, with the option to invest more at the same rate.
| Minimum Lot Investment (Retail) | 2 Lots |
| Maximum Lot Investment (Retail) | 2 Lots |
| HNI (Min) | 3 Lots |
Speciality Medicines IPO Allotment Status
To track the Status of the Allotment of IPOs of Speciality Medicines, you can go to the BSE site or the official Registrar site. Links to the site are provided below.
Using BSE Website - BSE IPO allotment status
Promoters And Management of Speciality Medicines Ltd.
- Parth B Goyani
- Goyani Sumit Babubhai.
| Pre-Issue Promoter Shareholding | 59.67% |
| Post-Issue Promoter Shareholding | - |
IPO Lead Managers
Unistone Capital Pvt. Ltd.
Dividend Policy
The Company has not paid any dividends in the last 3 years.
Conclusion
Specialty Medicines IPO presents a fair industry opportunity with a fair valuation (P/E ~8.79x), strong ROE (~37.85%), very low or no debt, and a diverse product portfolio targeting chronic conditions at a global level. The concern of supplier dependency, the flexible and varied product portfolio gives a strong position on the line of high margin-empty formulations to address the, driving high demand for formulations with the invested money on the line of exports, the line of R&D, the line of marketing and the line of registrations for the product formulations outside the country on the line of Regulatory Compliance.
To Apply for the IPO, Click Here.
To Read the Prospectus of the Company Click Here to Download the DRHP.
Disclaimer: The information provided in this blog is for educational and informational purposes only and should not be considered as investment advice, research, or a recommendation to buy, sell, or hold any securities. Stock market investments are subject to market risks. Readers are advised to read all scheme-related documents carefully and consult their financial advisor before making any investment decisions.
